Evidence map›Paper›PMID 29326661›Full record

ReviewFrontiers in microbiology2017

En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach.

Pierre-Louis Toutain, Alain Bousquet-Mélou, Peter Damborg, Aude A Ferran, Dik Mevius, Ludovic Pelligand, Kees T Veldman, Peter Lees

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in microbiology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
87citing papers in PubMed, 2 pooled it
10.5field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 167 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Molecular Characterization of Colistin-Resistant ClinicalAntibiotics (Basel, Switzerland) · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Veterinary sciences · 2024
    Review

27 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 4 countries.

Pierre-Louis ToutainUMR 1331 Toxalim, INRA, ENVT, Toulouse, France.
Alain Bousquet-MélouUMR 1331 Toxalim, INRA, ENVT, Toulouse, France.
Peter DamborgDepartment of Veterinary and Animal Sciences, University of Copenhagen, Frederiksberg, Denmark.
Aude A FerranUMR 1331 Toxalim, INRA, ENVT, Toulouse, France.
Dik MeviusWageningen Bioveterinary Research, Lelystad, Netherlands.
Ludovic PelligandThe Royal Veterinary College, University of London, London, United Kingdom.
Kees T VeldmanNational Reference Laboratory on Antimicrobial Resistance in Animals, Lelystad, Netherlands.
Peter LeesThe Royal Veterinary College, University of London, London, United Kingdom.
École Nationale Vétérinaire de Toulouse · FRRoyal Veterinary College · GBCNR de la Résistance aux Antibiotiques · FRToxalim Research Centre in Food Toxicology · FRUniversity of Copenhagen · DKWageningen University & Research · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

VetCAST is the EUCAST sub-committee for Veterinary Antimicrobial Susceptibility Testing. Its remit is to define clinical breakpoints (CBPs) for antimicrobial drugs (AMDs) used in veterinary medicine in Europe. This position paper outlines the procedures and reviews scientific options to solve challenges for the determination of specific CBPs for animal species, drug substances and disease conditions. VetCAST will adopt EUCAST approaches: the initial step will be data assessment; then procedures for decisions on the CBP; and finally the release of recommendations for CBP implementation. The principal challenges anticipated by VetCAST are those associated with the differing modalities of AMD administration, including mass medication, specific long-acting product formulations or local administration. Specific challenges comprise mastitis treatment in dairy cattle, the range of species and within species breed considerations and several other variable factors not relevant to human medicine. Each CBP will be based on consideration of: (i) an epidemiological cut-off value (ECOFF) - the highest MIC that defines the upper end of the wild-type MIC distribution; (ii) a PK/PD breakpoint obtained from pre-clinical pharmacokinetic data [this PK/PD break-point is the highest possible MIC for which a given percentage of animals in the target population achieves a critical value for the selected PK/PD index (

Indexed as

antimicrobialsAntimicrobial Susceptibility TestingbreakpointsVetCASTveterinary

Identifiers

PMID29326661
PMCPMC5736858
OpenAlexW2772528159

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.